Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness
Amneal Pharmaceuticals (AMRX) has experienced mixed share performance despite a strong one-year return, leading to a reassessment of its valuation. The company is considered 27.1% undervalued with a narrative fair value of $17.00, driven by strategic partnerships and expansion into high-growth categories. However, its current P/E ratio of 32.4x is higher than the industry average, which could indicate that optimism is already factored into the price.
Amneal (AMRX) director Deborah Autor sells 34,819 shares at $12.94 avg
Amneal Pharmaceuticals director Deborah M. Autor sold 34,819 shares of Class A Common Stock on May 11, 2026, at a weighted average price of $12.94 per share. Following this open-market transaction, her direct holdings in the company amount to 93,660 shares. The sale, valued at approximately $450,558, occurred in multiple trades ranging from $12.75 to $13.27.
Amneal Pharmaceuticals (AMRX) Profit Rebound Challenges Concerns Over Earnings Quality
Amneal Pharmaceuticals (AMRX) reported a profit rebound in FY 2025, with net income swinging to US$72.1 million, but the presence of a US$58.0 million one-off loss raises concerns about earnings quality. While a DCF fair value suggests the stock is undervalued, its high P/E ratio compared to peers and underlying financial risks like high debt and weak interest coverage create mixed opinions among investors. The article highlights that both bullish and bearish interpretations of AMRX's performance exist, urging investors to consider further analysis.
Amneal (NYSE: AMRX) director exercises 34,819 RSUs and receives new grant
Amneal Pharmaceuticals director J. Kevin Buchi exercised 34,819 restricted stock units (RSUs) on May 7, 2026, converting them into Class A Common shares at no cost, increasing his direct holdings to 75,077 shares. He also received a new grant of 19,824 RSUs on May 6, 2026. This activity is considered routine equity compensation and does not involve open-market stock purchases or sales.
Amneal Reports First Quarter 2026 Financial Results
Amneal Pharmaceuticals reported a strong start to 2026, with first-quarter net revenue of $723 million, GAAP net income of $62 million, and adjusted EBITDA of $202 million. The company affirmed its previously announced increased full-year 2026 guidance, citing strong performance in its Specialty business and growth in Affordable Medicines. Amneal's co-CEOs highlighted the diversified business and multiple growth drivers as key to its success.
[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity
Amneal Pharmaceuticals director Gautam Patel increased his equity stake through stock-based compensation. On May 7, 2026, he exercised 34,819 restricted stock units into Class A Common Stock at $0.00 per share, bringing his direct ownership to 1,643,963 shares. Additionally, on May 6, 2026, he was granted 19,824 restricted stock units that will vest according to the company's director vesting schedule.
Amneal (AMRX) director exercises RSUs, now holds 260,252 shares
Amneal Pharmaceuticals director John Kiely exercised 34,819 restricted stock units (RSUs) on May 7, 2026, receiving an equal number of Class A Common Stock shares at $0.00 per share. He also received a new RSU grant of 19,824 units on May 6, 2026. Following these transactions, Kiely directly owns 260,252 Class A Common Stock shares.
Director boosts stake with 34,819 shares in Amneal (NYSE: AMRX)
Amneal Pharmaceuticals director Ted C. Nark increased his equity stake by exercising 34,819 restricted stock units into Class A Common Stock shares on May 7, 2026. This transaction, part of a stock-based compensation, brought his direct holdings to 325,848 shares. Additionally, Nark received a new grant of 19,824 restricted stock units on May 6, 2026, with future vesting.
Amneal (NYSE: AMRX) director exercises 48,747 RSUs and receives 30,837-unit grant
Amneal Pharmaceuticals director Paul M. Meister recently exercised 48,747 Restricted Stock Units, converting them into Class A shares, increasing his direct holdings to 832,800 shares. Additionally, he was granted a new 30,837 Restricted Stock Unit award. These transactions, detailed in a Form 4 SEC filing, highlight recent equity compensation activities by a key insider at Amneal.
Amneal (NYSE: AMRX) director converts RSUs to shares and gets new grant
Amneal Pharmaceuticals director Yanai Shlomo increased his equity stake by exercising 34,819 restricted stock units (RSUs) into Class A Common Stock. He also received a new grant of 19,824 restricted stock units, further boosting his potential share ownership in the company. Following these transactions, Shlomo directly owns 320,804 shares of Amneal's Class A Common Stock.
Amneal Pharmaceuticals (NASDAQ: AMRX) posts Q1 profit surge and inks $375M Kashiv acquisition
Amneal Pharmaceuticals reported a significant surge in Q1 2026 profit, with net income more than tripling to $78.0 million and diluted EPS at $0.19, driven by higher gross margins and strong Specialty segment performance. The company also announced a definitive agreement to acquire Kashiv BioSciences for $375 million in cash, 28.9 million Class A shares, and up to $350 million in contingent payments, alongside a deal with MSN Laboratories for mirabegron distribution. Despite improved earnings, Amneal remains highly leveraged with $2.69 billion in debt and faces ongoing legal and settlement obligations, including $79.3 million for opioid litigation.
Amneal (NASDAQ: AMRX) Q1 2026 profit soars as margins rise and guidance held
Amneal Pharmaceuticals reported strong first-quarter 2026 results, with net revenue increasing by 4% to $722.5 million and net income attributable to Amneal soaring to $62.3 million from $12.2 million a year earlier. The company saw significant margin expansion due to growth in its Specialty segment and strategic portfolio adjustments within Affordable Medicines and AvKARE. Amneal reaffirmed its full-year 2026 guidance, projecting net revenue between $3.05 billion and $3.15 billion and adjusted diluted EPS of $0.95 to $1.05, despite a negative operating cash flow in Q1.
How CREXONT’s Positive Phase 4 Data and Reaffirmed Outlook Could Shape Amneal Pharmaceuticals (AMRX) Investors
Amneal Pharmaceuticals (AMRX) reported positive interim Phase 4 ELEVATE-PD data for CREXONT, showing improved "Good On" time and reduced "Off" time for Parkinson’s patients. Despite this clinical success, the company reaffirmed its 2026 revenue outlook of US$3.05 billion to US$3.15 billion, indicating that while the data supports a shift towards higher-value specialty neurology, the immediate financial impact is limited and the company still faces pressure from generics pricing. Investors need to consider this balanced view of branded growth versus ongoing generics market challenges.
Earnings Scheduled For May 1, 2026
This article lists numerous companies scheduled to report their quarterly earnings on May 1, 2026, both before and after the bell. It provides estimated earnings per share (EPS) and revenue figures for each company, offering a comprehensive preview for investors.
Is It Too Late To Reassess Amneal Pharmaceuticals (AMRX) After Its 65% One-Year Surge?
Amneal Pharmaceuticals (AMRX) has seen a significant 65.4% surge in its stock price over the last year. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 73.8% at $12.80 per share, with an intrinsic value of $48.82. However, its current P/E ratio of 56.67x is above the industry average and a proprietary "Fair Ratio" of 30.42x, indicating it might be overvalued based on earnings multiples.
Earnings call transcript: Amneal Pharma Q1 2026 beats EPS forecast
Amneal Pharmaceuticals Inc. (AMRX) reported strong Q1 2026 results, surpassing EPS forecasts with an adjusted EPS of $0.27 and revenue of $723 million. The company announced the acquisition of Kashiv BioSciences to become a fully integrated global biosimilars leader, anticipating significant growth and market diversification through this strategic move. Amneal also raised its full-year 2026 guidance, projecting 7-8% growth in affordable medicines and an increased total gross margin.
Amneal Kashiv Deal Shifts Biosimilar Growth And Valuation Story
Amneal Pharmaceuticals is acquiring Kashiv BioSciences to accelerate its biosimilar pipeline and create a fully integrated global biosimilars platform. This acquisition is expected to reshape Amneal's business mix towards biologics, diversifying its revenue base with multiple annual biosimilar launches planned by 2030. Despite recent stock declines, the deal positions Amneal to potentially enhance its long-term earnings profile and achieve analyst targets, though integration and interest coverage remain key considerations for investors.
2DT Stock Price and Chart — TRADEGATE:2DT
This article provides comprehensive financial data, news, and analyst ratings for Amneal Pharmaceuticals, Inc. Class A (2DT) traded on the Tradegate Exchange. It details the company's latest earnings, key financial stats, and outlines its business segments in pharmaceuticals. Additionally, the article discusses investment ideas, a recent opioid lawsuit settlement, and lists ETFs holding the stock.
Why Is Amneal Pharmaceuticals Stock Gaining Today?
Amneal Pharmaceuticals (NASDAQ: AMRX) shares are rising after the announcement of a definitive agreement to acquire Kashiv BioSciences for $1.1 billion. This acquisition aims to establish Amneal as a global leader in biosimilars, capitalizing on a projected $300 billion market opportunity and enhancing its growth profile, leading to raised full-year guidance for 2026. Technical analysis shows a strong upward trend, and analysts maintain a "Buy" rating with an average price target of $17.00.
Amneal (NASDAQ: AMRX) buys Kashiv and raises 2026 EBITDA, EPS and cash flow guidance
Amneal Pharmaceuticals (NASDAQ: AMRX) announced its agreement to acquire 100% of Kashiv BioSciences for $375 million in cash, 28,942,108 Class A shares, and up to $350 million in regulatory milestone payments, plus potential royalties. This acquisition aims to create a fully integrated global biosimilars platform. Concurrently, Amneal reported strong preliminary Q1 2026 results, with net revenue of $723 million, and consequently raised its 2026 guidance for adjusted EBITDA, adjusted diluted EPS, and operating cash flow.
Amneal to Buy Kashiv BioSciences for $375M Cash, 28.9M Shares; Milestones Up to $350M
Amneal Pharmaceuticals has entered an agreement to acquire Kashiv BioSciences for $375 million in cash and 28.9 million Class A shares. The deal also includes potential regulatory milestone payments of up to $350 million and a 25% royalty on certain products for 12 years. This acquisition aims to expand Amneal's pipeline in complex generics and specialty products and is expected to close in the second half of 2026.
Does Amneal Pharmaceuticals' (AMRX) Inhaler Push Reveal a Durable Edge in Complex Generics?
Amneal Pharmaceuticals recently launched generic metered-dose inhalers and an ophthalmic solution, expanding its presence in complex generics. This move highlights the company's capabilities in difficult-to-make products and supports its long-term investment narrative, focusing on offsetting pricing pressure and managing leverage. Despite the positive developments, investors should consider potential U.S. generics price pressure and varying fair value estimates for AMRX.
Should Amneal’s New Generic Glaucoma Launch Shape How AMRX Investors View Its Specialty Strategy?
Amneal Pharmaceuticals has launched bimatoprost ophthalmic solution 0.01%, a generic equivalent to Allergan’s LUMIGAN, adding a significant glaucoma treatment to its generics portfolio. This launch aligns with Amneal's strategy of expanding access to lower-cost chronic eye condition treatments, contributing to its reaffirmed 2026 revenue guidance of US$3.05 billion to US$3.15 billion. The article suggests investors should consider this within the broader context of Amneal's growth potential, pricing pressures, and leverage.
FOCUS-Patients scramble to find estrogen patches as shortage worsens after US FDA champions use
A significant surge in demand for estrogen patches, driven by the US FDA's changed stance on hormone replacement therapy (HRT), has led to widespread shortages. Patients are struggling to find supplies, leading to dose changes and "pharmacy-hopping," while manufacturers cite the complex and low-profit nature of generic patch production as a barrier to rapidly scaling up. Industry sources predict these shortages could persist for up to three years.
Is It Time To Reassess Amneal Pharmaceuticals (AMRX) After Its Strong Multi Year Share Price Run?
Amneal Pharmaceuticals (AMRX) has seen significant share price appreciation over recent years, prompting a reassessment of its valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 80.5% at its current price of US$12.80, estimating an intrinsic value of $65.67 per share. However, its current P/E ratio of 56.67x is considerably higher than the Pharmaceuticals industry average and its own calculated "Fair Ratio" of 18.57x, indicating it is overvalued based on earnings multiples.
Amneal Pharmaceuticals, Inc. Launches Bimatoprost Ophthalmic Solution 0.01%
Amneal Pharmaceuticals, Inc. has launched bimatoprost ophthalmic solution 0.01%, a generic equivalent to LUMIGAN. This product is intended to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. U.S. annual sales for LUMIGAN were approximately $719 million for the 12 months ending February 2026.
Amneal (NYSE: AMRX) Co-CEO receives major performance-based RSU award
Amneal Pharmaceuticals' Co-CEO, Chintu Patel, has been granted 544,663 performance-based restricted stock units (RSUs). These RSUs are tied to the company's Class A common stock performance over a three-year period, with vesting contingent on achieving specific average closing price targets. The actual number of shares received can range from 0% to 200% of the target, with full vesting scheduled for February 28, 2029, if conditions are met.
[Form 4/A] Amneal Pharmaceuticals, Inc. Amended Insider Trading Activity
Amneal Pharmaceuticals President & Co-CEO Chirag K. Patel has received a grant of 544,663 performance-based restricted stock units (RSUs) tied to Class A common stock. These RSUs are a compensation award that could convert into shares based on the company's stock performance over a three-year period. The number of shares ultimately received can range from 0% to 200% of the target, with full vesting on February 28, 2029, if earned.
Major holder Dipan Patel cuts Amneal Pharmaceuticals (AMRX) stake to 5.4%
Dipan Patel has reduced his beneficial ownership in Amneal Pharmaceuticals Inc. (AMRX) to 5.4% of Class A common stock, down from a previous holding. Through trusts he controls, Patel sold 6,924,729 shares in open market transactions between November 14, 2024, and December 31, 2025, at prices ranging from $7.74 to $12.42 per share. Following these sales, he retains sole voting and dispositive power over 16,904,263 shares.
How Amneal’s Margin-Focused 2026 Outlook and 2025 Results Could Impact Amneal Pharmaceuticals (AMRX) Investors
Amneal Pharmaceuticals (AMRX) reported 2025 revenues of US$3.02 billion and operating income of US$421 million, along with a 3.5x net leverage. Their 2026 guidance emphasizes modest revenue growth but faster adjusted EBITDA and EPS growth, driven by higher-margin products like biosimilars and new launches. This strategy aims to offset pricing pressure in generics and reshape investor perception towards margin-focused growth.
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Strong 2025 Results And 2026 Growth Guidance
Amneal Pharmaceuticals (AMRX) reported strong 2025 results with US$3.02 billion in revenue and US$421 million in operating income, and projected growth in adjusted EBITDA and EPS for 2026. Despite a recent share price pullback, the stock has shown significant long-term returns. Analysts suggest the stock is undervalued, estimating a fair value of $16.80 against a current price of $12.39, although its high P/E ratio compared to the industry indicates potential valuation risk.
What Amneal Pharmaceuticals (AMRX)'s Return to Profitability and 2026 Guidance Means For Shareholders
Amneal Pharmaceuticals reported strong fourth-quarter and full-year 2025 results, returning to profitability with net income of US$72.06 million and issuing optimistic 2026 net revenue guidance of US$3.05 billion to US$3.15 billion. The company's strategy involves a mix of generics, biosimilars, and specialty drugs, with future growth dependent on product launches, while managing high leverage remains a key risk for investors. Analysts project continued revenue and earnings growth, leading to a potential fair value upside for the stock.
Amneal (AMRX) EVP nets stock from RSU vesting and tax withholdings
Amneal Pharmaceuticals EVP Nikita Shah reported the vesting of restricted stock units (RSUs) and performance-based units, along with the disposition of shares to cover tax withholding obligations. Performance-based RSUs granted in 2023 vested at 200% of the targeted number due to the company's Class A stock performance. These transactions, detailed in a Form 4 SEC filing, reflect equity compensation rather than discretionary open market sales.
Amneal (AMRX) CFO earns 458,716 performance RSUs, with shares withheld for taxes
Amneal Pharmaceuticals' CFO, Tasos Konidaris, reported the vesting of multiple equity awards, including restricted stock units and performance-based restricted stock units. A significant grant of 458,716 performance-based RSUs vested at 200% of the target amount due to share-price conditions being met. Portions of the newly issued shares were withheld to cover tax obligations, rather than being sold in the open market, and Konidaris now directly holds 449,434 shares of Class A Common Stock.
AMRX SEC Filings - Amneal Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Amneal Pharmaceuticals (AMRX) SEC filings, including 10-K, 10-Q, and 8-K reports, designed for investors and traders. It highlights recent insider trading activities and sales by executives, detailing share disposals, option exercises, and proposed sales with specific dates and values. The platform also offers AI-powered tools to help users interpret these regulatory documents more efficiently.
Amneal (AMRX) Co-CEO gains shares via RSU and performance awards
Amneal Pharmaceuticals, Inc. (AMRX) Co-CEO Chirag K. Patel received Class A Common shares from the vesting of performance-based restricted stock units and additional restricted stock units. To cover tax withholding obligations, he disposed of a portion of these shares. Following these transactions, Patel's direct holdings include over 1.39 million Class A Common Stock shares and 185,185 restricted stock units, with an additional 21.2 million Class A shares held indirectly through family trusts.
Amneal (NYSE: AMRX) EVP Boyer settles RSUs, withholds stock for tax
Amneal Pharmaceuticals Executive Vice President Andrew S. Boyer recently settled various Restricted Stock Units (RSUs), including performance-based and time-based grants. These RSUs vested and were converted into Amneal Class A Common Stock. To cover tax obligations related to these vestings, Boyer had a portion of the shares withheld, with specific amounts at $13.31 and $13.30 per share. Following these transactions, Boyer directly holds 426,072 shares of Amneal Class A Common Stock.
Amneal (NYSE: AMRX) EVP Andrew Boyer granted time- and performance-based RSUs
Amneal Pharmaceuticals Executive Vice President Andrew S. Boyer has been granted 65,359 restricted stock units (RSUs) and 65,359 performance-based restricted stock units. The time-based RSUs will vest in four equal annual installments starting March 2, 2027, while the performance-based units are tied to average closing price targets of the company's Class A common stock over a three-year period ending February 28, 2029, with a potential payout from 0% to 200% of the target. This insider transaction was reported in a Form 4 SEC filing, indicating it as equity compensation rather than a cash purchase.
Amneal (NYSE: AMRX) CFO granted time- and performance-based RSUs
Amneal Pharmaceuticals' Executive Vice President & CFO, Tasos Konidaris, was granted 72,622 time-based Restricted Stock Units (RSUs) and 72,622 performance-based RSUs. The time-based units begin vesting in four equal annual installments starting March 2, 2027, while the performance-based units are tied to the company's average closing share price over a three-year period and can vest from 0% to 200% of the target, with full vesting on February 28, 2029, if conditions are met. This information was reported in a Form 4 SEC filing.
Amneal (NYSE: AMRX) grants RSU and performance stock awards to EVP
Amneal Pharmaceuticals (NYSE: AMRX) has granted its EVP and Chief Legal Officer, Jason B. Daly, two equity awards: 65,359 restricted stock units (RSUs) and 65,359 performance-based restricted stock units. The RSUs will vest in four equal annual installments starting March 2, 2027, while the performance-based units, tied to three-year stock price targets, will vest on February 28, 2029, with potential payouts ranging from 0% to 200% of the target.
Amneal (AMRX) Co-CEO awarded time- and performance-based RSUs
Amneal Pharmaceuticals President and Co-CEO Chirag K. Patel was granted 190,632 time-based restricted stock units (RSUs) and 354,031 performance-based RSUs, as reported in a Form 4 SEC filing. The time-based units vest in four equal annual installments starting March 2, 2027, while the performance-based units are tied to the company's average closing share price over a three-year period, with potential vesting from 0% to 200% of the target by February 28, 2029. This award signifies equity compensation valued at $0 per unit, with the ultimate value depending on future vesting and Amneal's share price.
Amneal (AMRX) Co-CEO Chintu Patel gets major RSU and PSU grants
Amneal Pharmaceuticals Co-CEO Chintu Patel received significant equity awards, including 190,632 restricted stock units (RSUs) vesting over four years and 354,031 performance-based restricted stock units (PSUs). The PSUs are tied to the company's stock price performance over a three-year period, with a potential payout ranging from 0% to 200% of the target shares. These grants align Patel's compensation with Amneal's long-term stock performance and continued service.
Amneal (NYSE: AMRX) EVP awarded time- and performance-based RSUs
Amneal Pharmaceuticals Executive Vice President Nikita Shah has been granted 65,359 time-based restricted stock units and 65,359 performance-based restricted stock units. The time-based units will vest in four equal annual installments starting March 2, 2027, while the performance-based units are tied to stock price targets over a three-year period, vesting on February 28, 2029, with a potential payout from 0% to 200%. This Form 4 filing details the equity awards as part of her compensation.
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following New 2026 Revenue Guidance Release
Amneal Pharmaceuticals recently released its 2026 revenue guidance, projecting net revenue between US$3.05 billion and US$3.15 billion. This new guidance clarifies management's expectations for the company's growth across generics, injectables, biosimilars, and specialty products. While supporting Amneal's diversification strategy, investors are encouraged to consider this outlook alongside ongoing pricing pressures, regulatory risks, and the recent nationwide opioids settlement.
Amneal Q4 2025 Highlights Shift Toward Higher Value Pharma Segments
Amneal Pharmaceuticals (NasdaqGS:AMRX) reported strong Q4 2025 results, demonstrating a strategic shift towards higher-value segments like specialty, injectables, biosimilars, and complex generics. The company announced multiple product launches, regulatory approvals, and highlighted a promising pipeline, including a collaboration with Pfizer on GLP-1 therapies. Analysts see the stock as undervalued, trading about 19% below the consensus target, while Simply Wall St's model estimates it is significantly below its fair value.
Earnings Scheduled For February 27, 2026
This article lists companies scheduled to report earnings on February 27, 2026, including their estimated earnings per share and revenue. It details both companies reporting before and after the market bell, providing financial projections from Benzinga's automated content engine.
Amneal Pharmaceuticals (AMRX) Return To Profit Tests High 60.3x P/E Narrative
Amneal Pharmaceuticals (AMRX) recently returned to profitability, reporting FY 2025 Q4 revenue of US$814.3 million and basic EPS of US$0.11, with trailing twelve-month revenue at US$3.0 billion and EPS of US$0.23. Despite this P/E of 60.3x and weak interest coverage raise concerns among investors, especially given the forecasted 4.9% annual revenue growth, which is below the broader market's 10.3% benchmark. The article highlights both bullish arguments, such as diversification into branded products, and bearish concerns regarding the high valuation and debt burden.
Amneal Pharmaceuticals Q4 Earnings Summary & Key Takeaways
Amneal Pharmaceuticals (NASDAQ: AMRX) released its Q4 earnings report, beating estimated earnings by 16.67% with an EPS of $0.21 against an estimate of $0.18. Revenue increased by $83.80 million year-over-year. The company also provided guidance for FY 2026, forecasting earnings between $0.93 and $1.03 per share.
Amneal (NASDAQ: AMRX) returns to profit and guides 2026 growth
Amneal Pharmaceuticals (NASDAQ: AMRX) reported a strong return to profitability in 2025 with net revenue of $3.02 billion and GAAP net income of $72 million. The company's adjusted EBITDA increased by 10% to $688 million, and adjusted diluted EPS rose to $0.83. Amneal also provided optimistic guidance for 2026, projecting net revenue between $3.05 billion and $3.15 billion, adjusted EBITDA of $720-$760 million, and adjusted diluted EPS of $0.93-$1.03, signaling continued growth and deleveraging.
Drugmaker Amneal swings from loss to $72M profit as sales hit $3B
Amneal Pharmaceuticals (Nasdaq: AMRX) reported strong Q4 and full-year 2025 financial results, achieving a net income of $72 million for the full year compared to a loss in 2024, with total net revenue reaching $3.02 billion. The company provided optimistic 2026 financial guidance, projecting net revenue between $3.05 billion and $3.15 billion and adjusted EBITDA of $720 million to $760 million, driven by growth in its Specialty and AvKARE segments and a robust pipeline of new product approvals. Investors reacted negatively on the day of the news, with AMRX declining 4.69%, despite the positive earnings report and future outlook.
